tebu-bio to provide CH3 BioSystems' product range throughout Europe
tebu-bio is pleased to announce their agreement with CH3 BioSystems to distribute their product range to the European market.
April 26, 2012 - PRLog -- Epigenetics is the study of heritable changes of phenotype that occur without alteration of the genome’s nucleotide sequence.
To date, existing molecular tools used for Epigenetic regulation have mostly focused on DNA modification. But, besides DNA changes, the post-translational modification of proteins also plays an important role in the regulation of gene expression. The rapidly expanding field of protein arginine methylation is a clear example of such new emerging needs in Epigenetic studies.
To answer these emerging needs, CH3 BioSystems, LLC develops high performance molecular tools and services for the discovery of protein methylation pathways in cells and tissues.
tebu-bio now brings European researchers access to CH3 BioSystems’ molecular tools, greatly facilitating the study of methyl marks on many different proteins.
John Aletta, Director of Research, CH3 BioSystems, LLC (Buffalo, NY, USA) commented on the deal "The timing of our agreement with tebu-bio coincides perfectly with the introduction of our expanded product line of cellular and molecular tools for Epigenetics Research. CH3 BioSystems is looking forward to a long and productive relationship with tebu-bio in service to the European R&D community.”
Philippe Fixe, Marketing Manager at tebu-bio (Le Perray-en-Yvelines, France) says: “We are very pleased to be able to offer our clients throughout Europe access to such innovative tools in the field of Epigenetics studies, which are now extremely widespread. These tools developed by CH3 BioSystems perfectly complement our existing range of products, offering researchers the possibility to explore the impact of methyl marks in the expression of their gene of interest”.
To find out more about CH3 BioSystems’ products available from tebu-bio, visit tebu-bio's website.
About CH3 BioSystems, LLC:
CH3 BioSystems is a biotechnology company based on an entirely new patent-protected chemical technology designed to identify and commercialize drug and diagnostic candidates. They manufacture novel molecular tools to help biomedical research better understand cancer and autoimmune, neurodevelopmental, viral and cardiovascular diseases that affect millions of people around the world.
CH3 BioSystems’ long-range vision is to facilitate the creation of diagnostic and pharmaceutical products that are based on the emerging new field of protein methylation biology.
tebu-bio is an expert in the supply & distribution of Life Sciences Lab Services & Reagents throughout Europe. Their own laboratories also provide R&D contract services. tebu-bio's online catalogue offers Life Science Researchers access to the most innovative range of over 650 000 references.